{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:40:38Z","timestamp":1790487638582,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Fibrocytes are monocyte-derived cells able to differentiate into myofibroblasts-like cells. We have previously shown that they are increased in the bronchi of Chronic Obstructive Pulmonary Disease (COPD) patients and associated to worse lung function. COPD is characterized by irreversible airflow obstruction, partly due to an increased cholinergic environment. Our goal was to investigate muscarinic signalling in COPD fibrocytes. Fibrocytes were isolated from 16 patients with COPD\u2019s blood and presence of muscarinic M3 receptor was assessed at the transcriptional and protein levels. Calcium signalling and collagen gels contraction experiments were performed in presence of carbachol (cholinergic agonist) \u00b1 tiotropium bromide (antimuscarinic). Expression of M3 receptor was confirmed by Western blot and flow cytometry in differentiated fibrocytes. Immunocytochemistry showed the presence of cytoplasmic and membrane-associated pools of M3. Stimulation with carbachol elicited an intracellular calcium response in 35.7% of fibrocytes. This response was significantly blunted by the presence of tiotropium bromide: 14.6% of responding cells (<jats:italic>p<\/jats:italic>&amp;lt; 0.0001). Carbachol induced a significant contraction of fibrocytes embedded in collagen gels (13.6 \u00b1 0.3% versus 2.5 \u00b1 4.1%;<jats:italic>p<\/jats:italic>&amp;lt; 0.0001), which was prevented by prior tiotropium bromide addition (4.1 \u00b1 2.7% of gel contraction;<jats:italic>p<\/jats:italic>&amp;lt; 0.0001). Finally, M3-expressing fibrocytes were also identified<jats:italic>in situ<\/jats:italic>in the peri-bronchial area of COPD patients\u2019 lungs, and there was a tendency to an increased density compared to healthy patient\u2019s lungs. In conclusion, around 1\/3 of COPD patients\u2019 fibrocytes express a functional muscarinic M3 receptor. Cholinergic-induced fibrocyte contraction might participate in airway diameter reduction and subsequent increase of airflow resistance in patients with COPD. The inhibition of these processes could participate to the beneficial effects of muscarinic antagonists for COPD treatment.<\/jats:p>","DOI":"10.3389\/fphar.2022.939780","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T06:15:42Z","timestamp":1662444942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Muscarinic receptor M3 activation promotes fibrocytes contraction"],"prefix":"10.3389","volume":"13","author":[{"given":"Pauline","family":"Henrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edm\u00e9e","family":"Eyraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Maurat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Point","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cardouat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Quignard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Esteves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Trian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Girodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Marthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00e9va","family":"Zysman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Dupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.4049\/jimmunol.2000909","article-title":"Blockade of PD-1\/PD-L1 pathway enhances the antigen-presenting capacity of fibrocytes","volume":"206","author":"Afroj","year":"2021","journal-title":"J. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1900475","article-title":"Update on the pathogenesis of chronic obstructive pulmonary disease","volume":"381","author":"Agust\u00ed","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1183\/09031936.00040709","article-title":"Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice","volume":"35","author":"Arai","year":"2010","journal-title":"Eur. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/0024-3205(95)00020-7","article-title":"Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease","volume":"56","author":"Barnes","year":"1995","journal-title":"Life Sci."},{"key":"B5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1183\/09031936.93.06030328","article-title":"Muscarinic receptor subtypes in airways","volume":"6","author":"Barnes","year":"1993","journal-title":"Eur. Respir. J."},{"key":"B6","unstructured":"Use of plerixafor for treating and\/or preventing acute exacerbations of chronic obstructive pulmonary disease BergerP. DupinI. GirodetP.-O. 2019"},{"key":"B7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1183\/09059180.00009902","article-title":"Reducing cholinergic constriction: The major reversible mechanism in COPD","volume":"15","author":"Brusasco","year":"2006","journal-title":"Eur. Respir. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/bf03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaci.2022.01.022","article-title":"Rhinovirus infection of bronchial epithelium induces specific bronchial smooth muscle cell migration of severe asthmatic patients","author":"Celle","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"L135","DOI":"10.1152\/ajplung.00084.2019","article-title":"TRPV4 channel mediates adventitial fibroblast activation and adventitial remodeling in pulmonary hypertension","volume":"318","author":"Cussac","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaci.2015.08.043","article-title":"Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway","volume":"137","author":"Dupin","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1165\/rcmb.2017-0301PS","article-title":"Fibrocytes in asthma and chronic obstructive pulmonary disease: Variations on the same theme","volume":"58","author":"Dupin","year":"2018","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1802173","DOI":"10.1183\/13993003.02173-2018","article-title":"Fibrocyte accumulation in the airway walls of COPD patients","volume":"54","author":"Dupin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/COPD.S160577","article-title":"Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD","volume":"13","author":"D\u2019Urzo","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1465-9921-7-73","article-title":"Muscarinic receptor signaling in the pathophysiology of asthma and COPD","volume":"7","author":"Gosens","year":"2006","journal-title":"Respir. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bbrc.2015.02.110","article-title":"Store-operated calcium entry: Mechanisms and modulation","volume":"460","author":"Hogan","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.2147\/COPD.S92412","article-title":"Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: A systematic review and network meta-analysis","volume":"10","author":"Ismaila","year":"2015","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"CD009285","DOI":"10.1002\/14651858.CD009285.pub2","article-title":"Tiotropium versus placebo for chronic obstructive pulmonary disease","volume":"2014","author":"Karner","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"B19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jcf.2020.06.011","article-title":"Fibrocyte accumulation in the lungs of cystic fibrosis patients","volume":"19","author":"Kasam","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.4049\/jimmunol.1400753","article-title":"Fibrocytes are not an essential source of type I collagen during lung fibrosis","volume":"193","author":"Kleaveland","year":"2014","journal-title":"J. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35557","DOI":"10.1074\/jbc.M405319200","article-title":"Mechanism of blebbistatin inhibition of myosin II","volume":"279","author":"Kov\u00e1cs","year":"2004","journal-title":"J. Biol. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse","year":"2012","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/cea.12421","article-title":"Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells","volume":"44","author":"Lin","year":"2014","journal-title":"Clin. Exp. Allergy"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eaav7384","DOI":"10.1126\/sciadv.aav7384","article-title":"Differentiated fibrocytes assume a functional mesenchymal phenotype with regenerative potential","volume":"5","author":"Ling","year":"2019","journal-title":"Sci. Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/thx.2006.070474","article-title":"Comparison of gel contraction mediated by airway smooth muscle cells from patients with and without asthma","volume":"62","author":"Matsumoto","year":"2007","journal-title":"Thorax"},{"key":"B27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1164\/rccm.200810-1534OC","article-title":"Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis","volume":"179","author":"Moeller","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pupt.2018.01.003","article-title":"Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus","volume":"49","author":"Naline","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9564","DOI":"10.1038\/s41598-019-45716-9","article-title":"Extracellular matrix stiffness regulates human airway smooth muscle contraction by altering the cell-cell coupling","volume":"9","author":"Polio","year":"2019","journal-title":"Sci. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4049\/jimmunol.171.1.380","article-title":"Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma","volume":"171","author":"Schmidt","year":"2003","journal-title":"J. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease","volume":"359","author":"Tashkin","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1172\/JCI93561","article-title":"Mechanosensing and fibrosis","volume":"128","author":"Tschumperlin","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/resp.14096","article-title":"Anti-IgE therapy inhibits chemotaxis, proliferation and transformation of circulating fibrocytes in patients with severe allergic asthma","volume":"26","author":"Wang","year":"2021","journal-title":"Respirology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.939780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T05:59:30Z","timestamp":1676699970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.939780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":33,"alternative-id":["10.3389\/fphar.2022.939780"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.939780","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"939780"}}